2-methoxyethyl N-ethylcarbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-methoxyethyl N-ethylcarbamate
• 化学式: C₆H₁₃NO₃
• 分子量: 147.174
• InChiKey: SOCDKKNSQIMMAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙二醇甲醚 、 N-乙基氨基甲酸甲酯 在 potassium hydroxide 作用下， 以 甲苯 为溶剂， 反应 20.0h， 生成 2-methoxyethyl N-ethylcarbamate
  参考文献：
  名称：

  碱催化转氨甲酰化

  摘要：

  无机碱如 NaH、KOt-Bu、NaOH 或 KOH 是在温和条件下促进氨基甲酸酯与各种伯醇和仲醇之间的氨基甲酰化反应的有效催化剂。它们构成了有机金属催化的替代品，可应用于脂肪族或芳香族聚氨酯。

  DOI：

  10.1055/s-0036-1588866

文献信息

• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。
• SOLID CATALYST FOR PROPYLENE POLYMERIZATION AND METHOD OF PRODUCING BLOCK COPOLYMER USING THE SAME
  申请人：Hanwha Total Petrochemical Co., Ltd.

  公开号：EP3670546A1

  公开（公告）日：2020-06-24

  The present invention relates to a solid catalyst for propylene polymerization and a method of producing a propylene polymer or copolymer using the solid catalyst for propylene polymerization, and provides a solid catalyst which prepares a dialkoxymagnesium carrier and is formed of a carrier produced through a reaction of the carrier with a metal halide, a titanium halide, an organic electron donor, etc., and a method of producing a propylene polymer or copolymer through copolymerization of propylene-alpha olefin using the solid catalyst, wherein the dialkoxymagnesium carrier has an uniform particle size range of 10 to 100 µm and a spherical particle shape by adjusting injection amounts, injection numbers, and reaction temperatures of metal magnesium, alcohol and a reaction initiator during a reaction process of metal magnesium and alcohol. Particularly, the present invention not only can produce polypropylene having high activity, excellent stereoregularity and hydrogen reactivity by performing a polymerization process through a solid catalyst which uses an internal electron donor including a carbonyl group and an alkoxy group out of two or more organic electron donors and is suggested in the present invention and a method of producing a propylene polymer or copolymer using the solid catalyst, but also can produce a block copolymer with a high rubber content by performing a copolymerization process with an alpha olefin.

  本发明涉及一种用于丙烯聚合的固体催化剂和一种使用该用于丙烯聚合的固体催化剂生产丙烯聚合物或共聚物的方法，并提供了一种固体催化剂，该催化剂制备了一种二羰基镁载体，并由载体与金属卤化物、钛卤化物、有机电子供体等反应生成的载体形成、以及使用该固体催化剂通过丙烯-α-烯烃的共聚生产丙烯聚合物或共聚物的方法，其中通过在金属镁和醇的反应过程中调整金属镁、醇和反应引发剂的注入量、注入次数和反应温度，该二烷氧基镁载体具有 10 至 100 微米的均匀粒径范围和球形颗粒形状。 特别是，本发明不仅可以通过固体催化剂进行聚合过程生产出具有高活性、优异立体规整性和氢反应性的聚丙烯，该固体催化剂使用了本发明中提出的在两个或多个有机电子供体中包括一个羰基和一个烷氧基的内部电子供体，以及使用该固体催化剂生产丙烯聚合物或共聚物的方法，还可以通过与α-烯烃进行共聚过程生产出橡胶含量高的嵌段共聚物。
• C6- AND C9-SUBSTITUTED CHROMENO[4,3-c]ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1532155B1

  公开（公告）日：2008-02-27
• ISOXAZOLINE-INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC AND ANXIOLYTIC A IVITY
  申请人：Janssen Pharmaceutica NV

  公开号：EP1819713B1

  公开（公告）日：2009-09-23
• Isoxazoline-Indole Derivatives With an Improved Antipsychotic and Anxiolytic Activity
  申请人：Andres-Gil Jose Ignacio

  公开号：US20080113988A1

  公开（公告）日：2008-05-15

  The present invention relates to novel isoxazoline-indole derivatives according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, with a binding affinity towards dopamine receptors, in particular towards dopamine D 2 and/or D 3 receptors, with selective serotonin reuptake inhibition (SSRI) properties and showing an affinity for the 5-HT 1A receptor, pharmaceutical compositions comprising the compounds according to the invention, the use thereof for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic disorders, most in particular schizophrenia and processes for their production, wherein the variables are further defined in the application.